Archive: Clinical Trial Participation

SubjectWell recently fielded a survey engaging over 300 type 2 diabetes patients. The findings showed that diabetes patients demonstrated high overall interest in clinical trial participation, but secondary conditions caused by their diabetes can shift that interest higher or lower. According to the CDC, more than 33 million Americans have type 2 diabetes. As patients’

In our most recent international survey of patients in Canada, South Africa and the US measuring the impact of healthcare usage, we found the country with the lowest healthcare usage overall and lowest trust in the healthcare system (South Africa) interestingly had the highest likelihood of clinical trial participation. However, when we took a closer

Quality care in any healthcare system relies heavily on patients developing and maintaining trust in their healthcare professionals (HCPs). As we’ve witnessed throughout the COVID-19 pandemic, local HCPs informing and guiding patients on proper treatment and preventive measures were more successful than similar messages pushed from government agencies or medical institutions. However, while patient trust

Marking more than a year since the pandemic began, the world has witnessed how essential clinical research is to creating safe, life-changing treatments. And, more specifically, people are clearly seeing how clinical trials have led to bringing the current coronavirus vaccines to market, now with more than 118 million doses administered in the US alone.

Known as the silent liver disease, nonalcoholic fatty liver disease (NAFLD) affects between 30% and 40% of all adults in the US. Fatty liver disease (FLD) can also lead to nonalcoholic steatohepatitis (NASH). Together, FLD and NASH impact the lives of more than 100 million Americans. And NASH is on the rise: by 2030, prevalent

Since the start of the pandemic, SubjectWell has kept a close eye on patient attitudes and feelings toward clinical trials. After all, right now is arguably the most critical time for clinical trial participation as COVID-19 cases continue to rise worldwide and vaccines and treatments are still being tested. By understanding what prevents or encourages

At SubjectWell, we continue to conduct surveys with patients to understand how their attitudes and feelings toward clinical trials have been altered in the wake of the pandemic. Having a grasp on these sentiments may now be more important than ever, as states continue the reopening process while positive cases continue to increase. Our most

In our ongoing effort to both understand patients’ evolving attitudes toward clinical trial participation in the face of COVID-19 and support our industry’s continued commitment to bringing novel treatments to market, SubjectWell completed the second of our recent insight surveys. We previously fielded surveys between March 19 and 23, 2020, to patients and sites throughout

Although real world evidence (RWE) is gaining steam in the healthcare industry, it doesn’t pose a threat to traditional clinical trials. Here’s what sponsors and CRO’s need to know:

Successful clinical trials depend on patients carefully following their treatment plans, but it can be difficult for sponsors and CROs to ensure adherence. Here’s how support programs can help.